Dustin Deming, MD
Combined DNA targeting and immunotherapy in the treatment of colorectal cancer
Currently immunotherapeutics are only beneficial for a small subset of patients with colorectal cancer who have deficiencies in DNA mismatch repair. Dr. Deming’s lab has recently generated data indicating the potential to enhance the immune response using precision medicine-based therapies. He will now utilize murine and patient-derived spheroid cultures to screen targeted therapies for their potential to enhance the immune response to immune checkpoint blockade, including PD-1 inhibitors for CRCs with specific mutation profiles of interest.